 An expanding body of clinical experience and controlled trials has established the efficacy of serotonin selective reuptake inhibitors SSRIs and the serotonin norepinephrine reuptake inhibitor SNRI venlafaxine, for the treatment of social anxiety disorder, with paroxetine, sertraline and venlafaxine extended-release XR, which are FDA approved for this indication. The newest SNRI, duloxetine, has been shown to be effective at doses of 60mgday to 120mgday for anxiety associated with depression, and is anticipated to be a broad spectrum agent for mood and anxiety disorders Dunner, Goldstein, Mallinckrodt, Lu, Detke, 2003. However, no data on the efficacy of duloxetine for Social Anxiety Disorder, nor guidance regarding time to response or predictors of response, is yet available. These questions are the focus of this proposal. 